Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss recent data from clinical studies of approved and investigational treatments for myelodysplastic syndromes
- Summarize optimal clinical management strategies for patients with intermediate-1–risk myelodysplastic syndromes and cytogenetic abnormalities
- Explain the differences between azacitidine and decitabine in the treatment of myelodysplastic syndromes
- Describe the use of erythropoiesis-stimulating agents in the treatment of myelodysplastic syndromes
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.